You will now be redirected to the GD3 website
Genesis Drug Discovery & Development is a proud member of Genesis Drug Discovery & Development (GD3), a fully integrated CRO providing services to support drug discovery programs of our clients from target discovery through IND filing and managing Phase I-III clinical trials.
Learn more about GD3DMPK
In Vivo DMPK
GD3 offers comprehensive preclinical pharmacokinetic and drug metabolism studies for rodents and rabbits. Our experienced scientists specialize in both systemic and ocular research, working with a diverse range of both small and large molecules including amino acids, nucleic acids, peptides, antibodies, and adeno-associated viruses.
For ocular dosing, we provide expert services from our trained research associates or a board-certified veterinary ophthalmologist. To complement pharmacokinetic studies, we offer a variety of pharmacodynamic endpoints, including OCT, FA, and ERG.
- Formulation screening
- Lead optimization
- Bioequivalence studies
- Bioavailability studies
- Biodistribution studies
- Pharmacokinetic studies
- Tolerability studies
- Maximum tolerated dose studies
- Single and multiple dose
- Systemic and ocular dosing
- Method development for novel dosing routes
- Pharmacodynamics endpoints
Routes of Administration:
-
Systemic:
- Oral gavage
- Subcutaneous
- Intravenous/infusion
- Intraperitoneal
- Intramuscular
- Dermal
- Intranasal inhalation/instillation
-
Ocular
- Intravitreal
- Intracameral
- Subretinal
- Suprachoroidal
- Subconjunctival
- Topical
Full necropsy capabilities, including extensive ocular dissection expertise:
-
Collection Anterior
- Aqueous humor, cornea, conjunctiva (palpebral and/or bulbar)
- Meibomian glands
- Trabecular meshwork, iris-ciliary body, lens
-
Posterior
- Vitreous humor, optic nerve
- Sclera, choroid (central and/or peripheral)
- Retina (central and/or peripheral)
Learn more about Bioanalysis